Search Clinical Trials in the EU

Duration

6-10 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

561-580 of 604 trials

Cognitive Improvement in Down Syndrome: Bumetanide Study

We are investigating whether Bumetanide can enhance cognitive functions in children and adolescents with Down syndrome aged 10-16. This study aims to explore its effects on both thinking skills and related psychological aspects.

Down Syndrome>2 yearsEfficacy phase (II)6-10 visits Standard MedicinesPediatricsPsychiatry

Low-Grade Upper Tract Urothelial Cancer: UGN-104 Treatment Study

We are studying a new treatment called UGN-104 for patients with low-grade upper tract urothelial cancer. The trial aims to see how well it reduces tumors and its safety compared to existing options.

Low-grade Upper Tract Urothelial Cancer1-2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncologyUrology

IgA Nephropathy: Felzartamab Infusions

We are studying the effects of felzartamab infusions on adults with IgA nephropathy to see if it helps reduce protein in urine and improve kidney function compared to a placebo.

IgA Nephropathy>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementInternal MedicineNephrology

Alopecia Areata: Ritlecitinib Study

We are investigating whether two doses of ritlecitinib can help people aged 12 and older with alopecia areata regrow their scalp hair. The study compares the effects of the medication to a placebo.

Alopecia Areata6-12 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteAllergologyDermatology

Glioblastoma: Adding Zoledronic Acid to Treatment

We are studying whether adding zoledronic acid to standard chemotherapy can help improve survival and treatment response in patients with glioblastoma. We also want to assess its safety and tolerability.

Glioblastoma3-6 monthsEfficacy phase (II)6-10 visits No Placebo Standard Medicines Partially RemoteNeurologyOncology

Type 1 Diabetes: Deferoxamine for Hypoxia Response

We are studying whether deferoxamine can improve how people with type 1 diabetes react to low oxygen levels. This trial will help us understand its potential benefits in managing diabetes.

Type 1 Diabetes>2 yearsEfficacy phase (II)6-10 visits Standard MedicinesEndocrinologyInternal Medicine

Solid Tumors: MK-5684 Study

We are testing a new treatment, MK-5684, for people with certain solid tumors to see if it helps them live longer without disease progression. The study also evaluates its safety and effectiveness compared to standard care.

Breast CancerOvarian CancerEndometrial Cancer6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visits No Placebo Standard MedicinesOncology

Insomnia in Adolescents: Melatonin vs. Quetiapine

We are studying whether melatonin or low-dose quetiapine can improve sleep in adolescents with psychiatric disorders and insomnia. We’ll also look at how these treatments affect overall well-being and daily functioning.

Psychiatric Disorders and Insomnia≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visits Standard Medicines Cost Reimbursement Partially RemotePsychiatry

Knee Surgery: Testing SRSD107 for Blood Clot Prevention

We are studying whether SRSD107 can effectively prevent blood clots in adults undergoing knee replacement surgery. We will also assess how safe it is compared to the standard treatment, enoxaparin.

Venous Thromboembolism6-12 monthsEfficacy phase (II)6-10 visits Investigational Medicines Cost Reimbursement Partially RemoteCardiologyOrthopedics and Traumatology

Hidradenitis Suppurativa: Tibulizumab Study

We are evaluating the effects of tibulizumab on skin lesions and quality of life for adults with hidradenitis suppurativa. The study also looks at the safety and tolerability of this treatment.

Hidradenitis Suppurativa6-12 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational MedicinesDermatology

Sickle Cell Disease: Tebapivat Study

We are investigating a new medication, tebapivat, to see if it helps improve anemia in people with sickle cell disease. The study will also look at its safety and effects on fatigue and pain.

Sickle Cell Disease3-6 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHematologyInternal Medicine

Vitamin D3 Supplementation: Young Adults vs. Seniors

We are comparing how vitamin D3 affects young adults and seniors to find the best supplementation approach for each group. The study also examines how respiratory illnesses might influence vitamin D levels.

Healthy Participants1-2 yearsConfirmation phase (III)6-10 visits No Placebo Standard MedicinesAllergologyDermatologyEndocrinologyInfectious DiseasesInternal MedicineNephrologyOphthalmologyOtolaryngologyPediatricsPsychiatryPulmonology

PM14 Treatment for Soft Tissue Sarcomas and Solid Tumors

We are studying how PM14 works alone and with radiotherapy in patients with soft tissue sarcomas and other solid tumors. The goal is to find the best treatment approach and understand its safety and effectiveness.

Soft Tissue Sarcomas and Other Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visits No Placebo Investigational MedicinesOncologyOrthopedics and Traumatology

Momelotinib for Anemia in Low-Risk Myelodysplastic Syndrome

We are studying whether momelotinib can improve red blood cell counts in patients with low-risk myelodysplastic syndrome. The trial also looks at the safety of this treatment.

Myelodysplastic Syndrome3-6 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteHematologyOncology

Rheumatoid Arthritis: Lower Dose of Rituximab Study

We are evaluating whether a 200 mg dose of Rituximab every six months is as effective as the standard 1 g dose for managing rheumatoid arthritis. This study will help us understand its impact on disease activity and overall patient well-being.

Rheumatoid Arthritis>2 yearsMonitoring phase (IV)6-10 visits No Placebo Standard Medicines Cost ReimbursementRheumatology

Psoriasis in Children: IDP-122 Lotion Study

We are testing a new lotion for children with moderate to severe plaque psoriasis to see how safe it is and how well it is absorbed into the body. This study will help us understand its effects on children's hormonal systems.

Plaque Psoriasis≤3 monthsEfficacy phase (II)6-10 visits No Placebo Investigational MedicinesDermatologyEndocrinology

Exenatide for Early Parkinson’s Disease Progression

We are studying whether Exenatide can slow down the progression of symptoms in people with early Parkinson’s disease. The trial will also assess the safety of this treatment over time.

Parkinson's Disease1-2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Partially RemoteEndocrinologyNeurology

Bisphosphonate Treatment for Primary Hyperparathyroidism

We are studying whether bisphosphonate treatment before parathyroid surgery can improve bone, kidney, and heart health one year after the procedure. This trial compares the treatment to a placebo to see if there are any benefits.

Primary Hyperparathyroidism1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visits Standard Medicines Cost ReimbursementEndocrinologyOrthopedics and Traumatology

Daratumumab for Myalgic Encephalomyelitis (ME/CFS)

We are studying whether the drug daratumumab can help reduce symptoms in people with moderate to severe ME/CFS. The trial will also assess its safety compared to a placebo.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome1-2 yearsEfficacy phase (II)6-10 visits Investigational Medicines Partially RemoteInfectious DiseasesNeurology

Refractory Epilepsy: YCJ-01 Cannabis Extract

We are studying a cannabis extract to see if it can help reduce seizures in patients with difficult-to-control epilepsy due to Tuberous Sclerosis Complex. The trial will also assess the safety of this treatment.

Tuberous Sclerosis ComplexRefractory Epilepsy in Tuberous Sclerosis Complex6-12 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

Search Clinical Trials in the European Union